Glenmark Launches Lacosamide Injection USP; Shares Rise 1.01%

Mumbai, June 5: Glenmark Pharmaceuticals Ltd announced that its US subsidiary has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials in the United States market.

The company said the product is bioequivalent and therapeutically equivalent to Vimpat Injection, 200 mg/20 mL (10 mg/mL), of UCB Inc. The launch expands Glenmark’s injectable product portfolio in the US generics market, according to an exchange filing submitted on June 5, 2026.

As per the regulatory disclosure, IQVIA sales data for the 12-month period ending April 2026 showed annual sales of approximately $15.2 million for the reference product market.

Marc Kikuchi, President and Business Head, North America, said the launch reflects the company’s strategy to broaden its differentiated product portfolio in the United States while improving patient access to affordable treatment options.

Stock Market Snapshot

Glenmark Pharmaceuticals share price rose after the product launch announcement during early trading on June 5, 2026.

The stock traded at ₹2,202.70, higher by 1.01% as of 9:21 AM IST on the NSE, according to exchange data. The positive movement followed investor reaction to the company’s latest US market expansion initiative.

Market participants tracked the development closely given the continuing focus on regulated market launches and injectable segment growth among Indian pharmaceutical exporters.

Glenmark Continues Focus on Regulated Markets

Glenmark Pharmaceuticals operates across branded formulations, generics, specialty products and consumer healthcare segments. The company maintains a presence in more than 80 countries with manufacturing facilities and research centres across multiple geographies.

According to company information shared in the release, Glenmark remains focused on respiratory, dermatology and oncology therapies while expanding its injectable and differentiated product pipeline in regulated markets.

The company ranked among the top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.

Product Launch Adds to US Generics Expansion Strategy

The latest launch underlines Glenmark’s continuing emphasis on complex generics and hospital-focused injectable therapies in the US pharmaceutical market.

Regulatory approvals and product commercialisation in the United States remain a key revenue driver for Indian pharmaceutical companies amid increasing competition in conventional oral solid dosage products. The company said the launch has been completed through Glenmark Pharmaceuticals Inc., USA, as per the exchange disclosure.

Source:

• https://www.nseindia.com/get-quote/equity/GLENMARK/Glenmark-Pharmaceuticals-Limited
• https://nsearchives.nseindia.com/corporate/GLENMARK_05062026084821_BSE_NSE_05062026_signed.pdf